

Tanya Stojkovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4336968/publications.pdf>

Version: 2024-02-01

224
papers

8,643
citations

41344

49
h-index

66911

78
g-index

273
all docs

273
docs citations

273
times ranked

10084
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic interest of whole-body MRI in early- and late-onset LAMA2 muscular dystrophies: a large international cohort. <i>Journal of Neurology</i> , 2022, 269, 2414-2429.	3.6	5
2	Charcot-Marie-Tooth disease type 2CC due to <i>NEFH</i> variants causes a progressive, non-length-dependent, motor-predominant phenotype. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 48-56.	1.9	9
3	Determinants of diaphragm inspiratory motion, diaphragm thickening, and its performance for predicting respiratory restrictive pattern in <i>Duchenne</i> muscular dystrophy. <i>Muscle and Nerve</i> , 2022, 65, 89-95.	2.2	3
4	Cramp-fasciculation syndrome phenotype of cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS) due to <i>RFC1</i> repeat expansion. <i>Clinical Neurophysiology</i> , 2022, 134, 34-36.	1.5	2
5	<i>RFC1</i> repeat expansions: A recurrent cause of sensory and autonomic neuropathy with cough and ataxia. <i>European Journal of Neurology</i> , 2022, 29, 2156-2161.	3.3	14
6	Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1850-1863.	7.3	12
7	Motor neuron pathology in CANVAS due to <i>RFC1</i> expansions. <i>Brain</i> , 2022, 145, 2121-2132.	7.6	32
8	Phenotypical variability and atypical presentations in a French cohort of Andersen-Tawil syndrome. <i>European Journal of Neurology</i> , 2022, 29, 2398-2411.	3.3	1
9	Unravelling the impact of frontal lobe impairment for social dysfunction in myotonic dystrophy type 1. <i>Brain Communications</i> , 2022, 4, .	3.3	5
10	Metformin rescues muscle function in <i>BAG3</i> myofibrillar myopathy models. <i>Autophagy</i> , 2021, 17, 2494-2510.	9.1	22
11	Clinical correlations and long-term follow-up in 100 patients with sarcoglycanopathies. <i>European Journal of Neurology</i> , 2021, 28, 660-669.	3.3	11
12	Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. <i>European Radiology</i> , 2021, 31, 4264-4276.	4.5	19
13	Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e40-e48.	3.9	32
14	The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre. <i>Brain Communications</i> , 2021, 3, fcab135.	3.3	16
15	Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study. <i>Journal of Neurology</i> , 2021, 268, 1792-1802.	3.6	16
16	Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. <i>Neurology</i> , 2021, 96, e2109-e2120.	1.1	38
17	Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale. <i>Annals of Neurology</i> , 2021, 89, 967-978.	5.3	17
18	Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in <i>Duchenne</i> muscular dystrophy—analysis of registry data. <i>European Heart Journal</i> , 2021, 42, 1976-1984.	2.2	25

#	ARTICLE	IF	CITATIONS
19	Deep phenotyping of an international series of patients with late-onset dysferlinopathy. <i>European Journal of Neurology</i> , 2021, 28, 2092-2102.	3.3	9
20	Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease. <i>Neuromuscular Disorders</i> , 2021, 31, 265-280.	0.6	18
21	A novel PHKA1 mutation associating myopathy and cognitive impairment: Expanding the spectrum of phosphorylase kinase b (Phk) deficiency. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117391.	0.6	3
22	Missense mutations in small muscle protein X-linked (SMPX) cause distal myopathy with protein inclusions. <i>Acta Neuropathologica</i> , 2021, 142, 375-393.	7.7	6
23	A form of muscular dystrophy associated with pathogenic variants in JAG2. <i>American Journal of Human Genetics</i> , 2021, 108, 840-856.	6.2	15
24	Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 1276-1286.	7.1	14
25	Genotype-phenotype correlation in French patients with <i>myelin protein zero</i> gene-related inherited neuropathy. <i>European Journal of Neurology</i> , 2021, 28, 2913-2921.	3.3	6
26	Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study. <i>European Journal of Neurology</i> , 2021, 28, 2846-2854.	3.3	22
27	Improved Cardiac Outcomes by Early Treatment with Angiotensin-Converting Enzyme Inhibitors in Becker Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 495-502.	2.6	3
28	Clinical and Molecular Spectrum Associated with COL6A3 c.7447A>G p.(Lys2483Glu) Variant: Elucidating its Role in Collagen VI-related Myopathies. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 633-645.	2.6	6
29	Leukoencephalopathy and conduction blocks in PLEKHG5-associated intermediate CMT disease. <i>Neuromuscular Disorders</i> , 2021, 31, 756-764.	0.6	3
30	High-Throughput Digital Image Analysis Reveals Distinct Patterns of Dystrophin Expression in Dystrophinopathy Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 955-965.	1.7	9
31	NEW GENES AND DISEASES. <i>Neuromuscular Disorders</i> , 2021, 31, S141-S142.	0.6	0
32	OTHER NMDs. <i>Neuromuscular Disorders</i> , 2021, 31, S156.	0.6	0
33	CHANNELOPATHIES AND RELATED DISORDERS. <i>Neuromuscular Disorders</i> , 2021, 31, S116.	0.6	0
34	A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 450.	2.7	9
35	European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A). <i>Journal of Neurology</i> , 2020, 267, 45-56.	3.6	43
36	Incidence and predictors of total mortality in 267 adults presenting with mitochondrial diseases. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 459-466.	3.6	11

#	ARTICLE	IF	CITATIONS
37	A high prevalence of arterial hypertension in patients with mitochondrial diseases. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 478-485.	3.6	5
38	SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES. <i>Neuromuscular Disorders</i> , 2020, 30, S99-S100.	0.6	0
39	CONGENITAL MUSCULAR DYSTROPHIES. <i>Neuromuscular Disorders</i> , 2020, 30, S105-S106.	0.6	0
40	Pathogenic Variants in the Myosin Chaperone UNC-45B Cause Progressive Myopathy with Eccentric Cores. <i>American Journal of Human Genetics</i> , 2020, 107, 1078-1095.	6.2	24
41	COVID-19-related encephalopathy: a case series with brain FDG-positron emission tomography/computed tomography findings. <i>European Journal of Neurology</i> , 2020, 27, 2651-2657.	3.3	127
42	Demyelinating Charcot-Marie-Tooth neuropathy associated with FBLN5 mutations. <i>European Journal of Neurology</i> , 2020, 27, 2568-2574.	3.3	2
43	Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. <i>Nature Genetics</i> , 2020, 52, 473-481.	21.4	97
44	GGPS1 Mutations Cause Muscular Dystrophy/Hearing Loss/Ovarian Insufficiency Syndrome. <i>Annals of Neurology</i> , 2020, 88, 332-347.	5.3	22
45	Genomic sequencing highlights the diverse molecular causes of Perrault syndrome: a peroxisomal disorder (PEX6), metabolic disorders (CLPP, GGPS1), and mtDNA maintenance/translation disorders (LARS2, TFAM). <i>Human Genetics</i> , 2020, 139, 1325-1343.	3.8	21
46	Ganglionopathies Associated with MERRF Syndrome: An Original Report. <i>Journal of Neuromuscular Diseases</i> , 2020, 7, 419-423.	2.6	4
47	Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification. <i>American Journal of Human Genetics</i> , 2020, 106, 412-421.	6.2	47
48	Confounding clinical presentation and different disease progression in CMT4B1. <i>Neuromuscular Disorders</i> , 2020, 30, 576-582.	0.6	1
49	Mutation m.3395A>G in MT-ND1 leads to variable pathologic manifestations. <i>Human Molecular Genetics</i> , 2020, 29, 980-989.	2.9	5
50	Brody myopathy demonstrates a pseudo-increment on repetitive nerve stimulation. <i>Muscle and Nerve</i> , 2020, 61, 491-495.	2.2	2
51	Cerebellar ataxia, neuropathy, vestibular areflexia syndrome due to RFC1 repeat expansion. <i>Brain</i> , 2020, 143, 480-490.	7.6	140
52	Novel CAPN3 variant associated with an autosomal dominant calpainopathy. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 564-578.	3.2	20
53	Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. <i>Revue Neurologique</i> , 2020, 176, 507-515.	1.5	71
54	A new congenital multicore titinopathy associated with fast myosin heavy chain deficiency. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 846-854.	3.7	8

#	ARTICLE	IF	CITATIONS
55	Intensive Teenage Activity Is Associated With Greater Muscle Hyperintensity on T1W Magnetic Resonance Imaging in Adults With Dysferlinopathy. <i>Frontiers in Neurology</i> , 2020, 11, 613446.	2.4	3
56	MRI " MUSCLE IMAGING. <i>Neuromuscular Disorders</i> , 2019, 29, S153-S154.	0.6	0
57	DISORDERS OF THE EXTRACELLULAR MATRIX. <i>Neuromuscular Disorders</i> , 2019, 29, S192-S193.	0.6	0
58	Hereditary sensory autonomic neuropathy type II: Report of two novel mutations in the FAM134B gene. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 354-358.	3.1	9
59	Novel Phenotypes and Cardiac Involvement Associated With DNA2 Genetic Variants. <i>Frontiers in Neurology</i> , 2019, 10, 1049.	2.4	6
60	Scapular dyskinesia in myotonic dystrophy type 1: clinical characteristics and genetic investigations. <i>Journal of Neurology</i> , 2019, 266, 2987-2996.	3.6	1
61	Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination. <i>Brain</i> , 2019, 142, 2948-2964.	7.6	43
62	Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. <i>Journal of Neurology</i> , 2019, 266, 680-690.	3.6	31
63	Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. <i>Circulation</i> , 2019, 140, 293-302.	1.6	131
64	<i>PDXK</i> mutations cause polyneuropathy responsive to pyridoxal 5-phosphate supplementation. <i>Annals of Neurology</i> , 2019, 86, 225-240.	5.3	54
65	Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial endpoints. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1033-1045.	3.7	28
66	A multicenter retrospective study of charcot-Marie-Tooth disease type 4B (CMT4B) associated with mutations in myotubularin-related proteins (MTMRs). <i>Annals of Neurology</i> , 2019, 86, 55-67.	5.3	35
67	Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene. <i>Neuromuscular Disorders</i> , 2019, 29, 497-502.	0.6	7
68	LRSAM1 variants and founder effect in French families with ataxic form of Charcot-Marie-Tooth type 2. <i>European Journal of Human Genetics</i> , 2019, 27, 1406-1418.	2.8	5
69	FSHD1 and FSHD2 form a disease continuum. <i>Neurology</i> , 2019, 92, e2273-e2285.	1.1	50
70	Diaphragm sniff ultrasound: Normal values, relationship with sniff nasal pressure and accuracy for predicting respiratory involvement in patients with neuromuscular disorders. <i>PLoS ONE</i> , 2019, 14, e0214288.	2.5	25
71	Congenital myopathies are mainly associated with a mild cardiac phenotype. <i>Journal of Neurology</i> , 2019, 266, 1367-1375.	3.6	10
72	Assessment of diaphragm motion using ultrasonography in a patient with facio-scapulo-humeral dystrophy. <i>Medicine (United States)</i> , 2019, 98, e13887.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Echographic Assessment of Diaphragmatic Function in Duchenne Muscular Dystrophy from Childhood to Adulthood. <i>Journal of Neuromuscular Diseases</i> , 2019, 6, 55-64.	2.6	11
74	A novel nonsense PIEZO2 mutation in a family with scoliosis and proprioceptive defect. <i>Neuromuscular Disorders</i> , 2019, 29, 75-79.	0.6	13
75	Assessment of disease progression in dysferlinopathy. <i>Neurology</i> , 2019, 92, .	1.1	20
76	Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas. <i>European Journal of Neurology</i> , 2019, 26, 497.	3.3	25
77	Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 576-585.	1.9	38
78	The spinal and cerebral profile of adult spinal-muscular atrophy: A multimodal imaging study. <i>NeuroImage: Clinical</i> , 2019, 21, 101618.	2.7	54
79	A new case of SMA phenotype without epilepsy due to biallelic variants in <i>ASAH1</i> . <i>European Journal of Human Genetics</i> , 2019, 27, 337-339.	2.8	7
80	Novel mutations in <i>DNAJB6</i> cause LGMD1D and distal myopathy in French families. <i>European Journal of Neurology</i> , 2018, 25, 790-794.	3.3	23
81	Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1. <i>JAMA Neurology</i> , 2018, 75, 573.	9.0	32
82	WES homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy reveals intronic <i>GDAP1</i> variant leading to a premature stop codon. <i>Neurogenetics</i> , 2018, 19, 67-76.	1.4	5
83	Hearing impairment in patients with myotonic dystrophy type 2. <i>Neurology</i> , 2018, 90, e615-e622.	1.1	11
84	The role of electrodiagnosis with long exercise test in mcardle disease. <i>Muscle and Nerve</i> , 2018, 58, 64-71.	2.2	5
85	Genotype and other determinants of respiratory function in myotonic dystrophy type 1. <i>Neuromuscular Disorders</i> , 2018, 28, 222-228.	0.6	17
86	Diaphragm: Pathophysiology and Ultrasound Imaging in Neuromuscular Disorders. <i>Journal of Neuromuscular Diseases</i> , 2018, 5, 1-10.	2.6	57
87	Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. <i>Acta Oncologica</i> , 2018, 57, 403-411.	1.8	22
88	Rigid spine syndrome associated with sensory-motor axonal neuropathy resembling Charcot-Marie-Tooth disease is characteristic of <i>BCL2L1</i> associated athanogene gene mutations even without cardiac involvement. <i>Muscle and Nerve</i> , 2018, 57, 330-334.	2.2	17
89	Spastic paraplegia due to <i>SPAST</i> mutations is modified by the underlying mutation and sex. <i>Brain</i> , 2018, 141, 3331-3342.	7.6	72
90	Isokinetic assessment of trunk muscles in facioscapulohumeral muscular dystrophy type 1 patients. <i>Neuromuscular Disorders</i> , 2018, 28, 996-1002.	0.6	2

#	ARTICLE	IF	CITATIONS
91	High Risk of Fatal and Nonfatal Venous Thromboembolism in Myotonic Dystrophy. <i>Circulation</i> , 2018, 138, 1169-1171.	1.6	2
92	Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation. <i>BMJ Open</i> , 2018, 8, e021632.	1.9	36
93	The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy. <i>Clinical Neurophysiology</i> , 2018, 129, 2333-2340.	1.5	33
94	MFN2-associated lipomatosis: Clinical spectrum and impact on adipose tissue. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1420-1435.	1.5	47
95	Longitudinal upper limb muscle MRI in dysferlinopathy: examining the relationship between semi quantitative MRI and physiotherapy outcome measures. <i>Neuromuscular Disorders</i> , 2018, 28, S6-S7.	0.6	0
96	Is cardiac dysfunction a feature of dysferlinopathy? Data from the Clinical Outcome Study of Dysferlinopathy. <i>Neuromuscular Disorders</i> , 2018, 28, S5-S6.	0.6	1
97	Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1071-1081.	1.9	81
98	Non invasive mechanical ventilation in DM1: The strong correlation between lung function, neurological-cognitive function and CTG repeats. <i>Neuromuscular Disorders</i> , 2018, 28, 894-895.	0.6	0
99	Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. <i>European Heart Journal</i> , 2017, 38, ehw569.	2.2	59
100	Axonal Neuropathies due to Mutations in Small Heat Shock Proteins: Clinical, Genetic, and Functional Insights into Novel Mutations. <i>Human Mutation</i> , 2017, 38, 556-568.	2.5	54
101	Phenotypic spectrum of Charcotâ€ˆMarieâ€ˆTooth disease due to <i>LITAF</i> mutations: a study of 18 patients. <i>European Journal of Neurology</i> , 2017, 24, 530-538.	3.3	9
102	Genetic Characterization of a French Cohort of GNEâ€ˆmutation negative inclusion body myopathy patients with exome sequencing. <i>Muscle and Nerve</i> , 2017, 56, 993-997.	2.2	6
103	Hyperckemia and myalgia are common presentations of anoctaminâ€ˆrelated myopathy in French patients. <i>Muscle and Nerve</i> , 2017, 56, 1096-1100.	2.2	34
104	The diagnostic value of hyperammonaemia induced by the non-ischaemic forearm exercise test. <i>Journal of Clinical Pathology</i> , 2017, 70, 896-898.	2.0	4
105	Two-dimensional electrophoresis highlights haptoglobin beta chain as an additional biomarker of congenital disorders of glycosylation. <i>Clinica Chimica Acta</i> , 2017, 470, 70-74.	1.1	11
106	Motor neuron disease of very long disease duration or Charcotâ€ˆMarieâ€ˆTooth disease? A novel phenotype related to the SOD1 p.E22G variant. <i>Revue Neurologique</i> , 2017, 173, 671-673.	1.5	1
107	High intra-familial clinical variability in MORC2 mutated CMT2 patients. <i>Brain</i> , 2017, 140, e21-e21.	7.6	14
108	Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy. <i>Journal of Neurology</i> , 2017, 264, 1791-1803.	3.6	26

#	ARTICLE	IF	CITATIONS
109	Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 80-85.	1.1	21
110	Risk for Complications after Pacemaker or Cardioverter Defibrillator Implantations in Patients with Myotonic Dystrophy Type 1. <i>Journal of Neuromuscular Diseases</i> , 2017, 4, 175-181.	2.6	5
111	Reversible endogenous downregulation of myostatin pathway in wasting neuromuscular diseases explains challenges of anti-myostatin therapeutic approaches. <i>Neuromuscular Disorders</i> , 2017, 27, S97-S98.	0.6	0
112	Affected female carriers of MTM1 mutations display a wide spectrum of clinical and pathological involvement: delineating diagnostic clues. <i>Acta Neuropathologica</i> , 2017, 134, 889-904.	7.7	42
113	Diagnosis of unilateral trapezius muscle palsy: 54 Cases. <i>Muscle and Nerve</i> , 2017, 56, 215-223.	2.2	24
114	Recessive mutations in the kinase ZAK cause a congenital myopathy with fibre type disproportion. <i>Brain</i> , 2017, 140, 37-48.	7.6	28
115	Tubular aggregate myopathy with features of Stormorken disease due to a new STIM1 mutation. <i>Neuromuscular Disorders</i> , 2017, 27, 78-82.	0.6	36
116	Prediction of long-term prognosis by heteroplasmy levels of the m.3243A>G mutation in patients with the <scp>mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes</scp> syndrome. <i>European Journal of Neurology</i> , 2017, 24, 255-261.	3.3	41
117	Corrigendum to "22nd International Congress of the World Muscle Society, Saint Malo, France, 3rd-7th October 2017" [<i>Neuromuscular Disorders</i> 27S2 (2017) S51-S270]. <i>Neuromuscular Disorders</i> , 2017, 27, e1.	0.6	0
118	Natural History of Cardiac and Respiratory Involvement, Prognosis and Predictive Factors for Long-Term Survival in Adult Patients with Limb Girdle Muscular Dystrophies Type 2C and 2D. <i>PLoS ONE</i> , 2016, 11, e0153095.	2.5	36
119	Non Random Distribution of DMD Deletion Breakpoints and Implication of Double Strand Breaks Repair and Replication Error Repair Mechanisms. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 227-245.	2.6	11
120	Relationship between muscle impairments, postural stability, and gait parameters assessed with lower-trunk accelerometry in myotonic dystrophy type 1. <i>Neuromuscular Disorders</i> , 2016, 26, 428-435.	0.6	22
121	High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. <i>Brain</i> , 2016, 139, 2131-2135.	7.6	202
122	Variants in the Oxidoreductase PYROXD1 Cause Early-Onset Myopathy with Internalized Nuclei and Myofibrillar Disorganization. <i>American Journal of Human Genetics</i> , 2016, 99, 1086-1105.	6.2	45
123	Hereditary neuropathies: An update. <i>Revue Neurologique</i> , 2016, 172, 775-778.	1.5	42
124	The Clinical Outcome Study for dysferlinopathy. <i>Neurology: Genetics</i> , 2016, 2, e89.	1.9	75
125	TRPV4 gene polymorphism as a phenotype modifier in a family with COL6-linked Bethlem myopathy. <i>Neuromuscular Disorders</i> , 2016, 26, S188.	0.6	1
126	A novel DNAJB6 mutation causing variable phenotypic expression: From distal myopathy to limb girdle muscular dystrophy. <i>Neuromuscular Disorders</i> , 2016, 26, S93-S94.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Peripheral neuropathy in glycogen storage disease type III: Fact or myth?. <i>Muscle and Nerve</i> , 2016, 53, 310-312.	2.2	7
128	Atrial flutter in myotonic dystrophy type 1: Patient characteristics and clinical outcome. <i>Neuromuscular Disorders</i> , 2016, 26, 227-233.	0.6	19
129	Cervical Spinal Cord Atrophy Profile in Adult SMN1-Linked SMA. <i>PLoS ONE</i> , 2016, 11, e0152439.	2.5	16
130	Mosaicism for Dominant Collagen 6 Mutations as a Cause for Intrafamilial Phenotypic Variability. <i>Human Mutation</i> , 2015, 36, 48-56.	2.5	28
131	Laminin ± 2 Deficiency-Related Muscular Dystrophy Mimicking Emery-Dreifuss and Collagen VI related Diseases. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 229-240.	2.6	30
132	Respiratory muscle dysfunction in facioscapulohumeral muscular dystrophy. <i>Neuromuscular Disorders</i> , 2015, 25, 632-639.	0.6	20
133	Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases. <i>European Heart Journal</i> , 2015, 36, 2886-2893.	2.2	71
134	Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. <i>Neurology</i> , 2015, 84, 1772-1781.	1.1	50
135	Myofibrillar myopathies: State of the art, present and future challenges. <i>Revue Neurologique</i> , 2015, 171, 715-729.	1.5	38
136	Diagnostic power of the non-ischaemic forearm exercise test in detecting glycogenosis type V. <i>European Journal of Neurology</i> , 2015, 22, 933-940.	3.3	22
137	A novel mutation in DNAJB6 causes LGMD1D in two French families. <i>Neuromuscular Disorders</i> , 2015, 25, S236.	0.6	1
138	Charcot-Marie-Tooth type 4B1 (MTMR2 gene): Confounding clinical presentation and report of 5 original mutations. <i>Neuromuscular Disorders</i> , 2015, 25, S285.	0.6	0
139	Antibodies to clustered acetylcholine receptor: expanding the phenotype. <i>European Journal of Neurology</i> , 2014, 21, 130-134.	3.3	51
140	Charcot-Marie-Tooth Disease Type 2A. <i>JAMA Neurology</i> , 2014, 71, 1036.	9.0	105
141	Clinical spectrum and gender differences in a large cohort of Charcot-Marie-Tooth type 1A patients. <i>Journal of the Neurological Sciences</i> , 2014, 336, 155-160.	0.6	22
142	Multiple Phenotypes in Phosphoglucomutase 1 Deficiency. <i>New England Journal of Medicine</i> , 2014, 370, 533-542.	27.0	236
143	G.P.72. <i>Neuromuscular Disorders</i> , 2014, 24, 816.	0.6	0
144	G.P.268. <i>Neuromuscular Disorders</i> , 2014, 24, 897.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Quantitative Magnetic Resonance Imaging in Limb-Girdle Muscular Dystrophy 2I: A Multinational Cross-Sectional Study. <i>PLoS ONE</i> , 2014, 9, e90377.	2.5	81
146	Pregnancy in congenital myasthenic syndrome. <i>Journal of Neurology</i> , 2013, 260, 815-819.	3.6	24
147	Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 635-643.	1.6	51
148	Muscle diseases with prominent joint contractures: Main entities and diagnostic strategy. <i>Revue Neurologique</i> , 2013, 169, 546-563.	1.5	13
149	Sensory chronic inflammatory demyelinating polyneuropathy: An under-recognized entity?. <i>Muscle and Nerve</i> , 2013, 48, 727-732.	2.2	68
150	P.12.6 Congenital myasthenic syndromes: Diagnosis difficulties, course and prognosis, and therapy – The French CMS network experience. <i>Neuromuscular Disorders</i> , 2013, 23, 806-807.	0.6	0
151	Dilated cardiomyopathy in patients with mutations in anoctamin 5. <i>International Journal of Cardiology</i> , 2013, 168, 76-79.	1.7	56
152	Neutral lipid storage disease with myopathy: A whole-body nuclear MRI and metabolic study. <i>Molecular Genetics and Metabolism</i> , 2013, 108, 125-131.	1.1	27
153	Anoctamin 5 myopathy: More patients, more phenotypes. <i>Journal of the Neurological Sciences</i> , 2013, 333, e447.	0.6	1
154	Fat and Carbohydrate Metabolism During Exercise in Phosphoglucomutase Type 1 Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1235-E1240.	3.6	26
155	Skeletal Muscle Biopsy Analysis in Reducing Body Myopathy and Other FHL1-Related Disorders. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 833-845.	1.7	36
156	Quantitative Muscle MRI as an Assessment Tool for Monitoring Disease Progression in LGMD2I: A Multicentre Longitudinal Study. <i>PLoS ONE</i> , 2013, 8, e70993.	2.5	148
157	Electrophysiological Study With Prophylactic Pacing and Survival in Adults With Myotonic Dystrophy and Conduction System Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1292.	7.4	154
158	Clinical and electrophysiological characteristics of neuropathy associated with Tangier disease. <i>Journal of Neurology</i> , 2012, 259, 1222-1226.	3.6	28
159	Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations. <i>Neuromuscular Disorders</i> , 2012, 22, 318-324.	0.6	64
160	High cardiovascular morbidity and mortality in myofibrillar myopathies due to DES gene mutations: a 10-year longitudinal study. <i>Neuromuscular Disorders</i> , 2012, 22, 211-218.	0.6	49
161	Heterogeneous spectrum of neuropathies in Waldenström's macroglobulinemia: a diagnostic strategy to optimize their management. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 90-101.	3.1	47
162	Characteristics of clinical and electrophysiological pattern of Charcot-Marie-Tooth 4C. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 112-122.	3.1	40

#	ARTICLE	IF	CITATIONS
163	Impaired myocardial deformation detected by speckle-tracking echocardiography in patients with myotonic dystrophy type 1. <i>International Journal of Cardiology</i> , 2011, 152, 375-376.	1.7	15
164	Erratum to "Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget's disease of bone and frontotemporal dementia" [Neuromuscular Disorders 19 (2009) 316-323]. <i>Neuromuscular Disorders</i> , 2011, 21, e1.	0.6	0
165	P5.17 Congenital Myasthenic Syndromes with COLQ mutations: Long term follow-up. <i>Neuromuscular Disorders</i> , 2011, 21, 728-729.	0.6	1
166	Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies. <i>Acta Neuropathologica</i> , 2011, 121, 253-266.	7.7	113
167	Long-term observational study of sporadic inclusion body myositis. <i>Brain</i> , 2011, 134, 3176-3184.	7.6	319
168	Morphologic imaging in muscular dystrophies and inflammatory myopathies. <i>Skeletal Radiology</i> , 2010, 39, 1219-1227.	2.0	76
169	Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7. <i>Journal of Neurology</i> , 2010, 257, 754-766.	3.6	70
170	Early onset collagen VI myopathies: Genetic and clinical correlations. <i>Annals of Neurology</i> , 2010, 68, 511-520.	5.3	112
171	A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 50-56.	3.1	140
172	Differentiating Emery-Dreifuss muscular dystrophy and collagen VI-related myopathies using a specific CT scanner pattern. <i>Neuromuscular Disorders</i> , 2010, 20, 517-523.	0.6	31
173	P2.37 Long term prognosis of congenital myasthenic syndromes (CMS): The French CMS network experience. <i>Neuromuscular Disorders</i> , 2010, 20, 629-630.	0.6	0
174	Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2009, 8, 1103-1110.	10.2	114
175	Differential involvement of sarcomeric proteins in myofibrillar myopathies: a morphological and immunohistochemical study. <i>Acta Neuropathologica</i> , 2009, 117, 293-307.	7.7	67
176	Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2009, 256, 134-136.	3.6	8
177	Mutations of the FHL1 Gene Cause Emery-Dreifuss Muscular Dystrophy. <i>American Journal of Human Genetics</i> , 2009, 85, 338-353.	6.2	208
178	Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget's disease of bone and frontotemporal dementia. <i>Neuromuscular Disorders</i> , 2009, 19, 316-323.	0.6	79
179	EM.P.4.02 Comprehensive clinical, cellular and molecular assessment of 64 French families with COL6-related muscle disorders: Clues for genotype/phenotype correlations. <i>Neuromuscular Disorders</i> , 2009, 19, 606-607.	0.6	0
180	G.P.16.06 Anti-SRP antibody myopathies: clinical characteristics and follow-up of 24 patients. <i>Neuromuscular Disorders</i> , 2009, 19, 652-653.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Muscle Glycogenosis Due to Phosphoglucomutase 1 Deficiency. <i>New England Journal of Medicine</i> , 2009, 361, 425-427.	27.0	101
182	Ullrich Congenital Dystrophy and Bethlem Myopathy: Current Knowledge on the Clinical Spectrum, Pathogenesis, and Future Therapeutic Avenues of Collagen VI Related Muscular Dystrophies. <i>Current Pediatric Reviews</i> , 2009, 5, 28-35.	0.8	2
183	A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: Clinical and pathological findings. <i>Neuromuscular Disorders</i> , 2008, 18, 334-338.	0.6	43
184	Electron microscopy in myofibrillar myopathies reveals clues to the mutated gene. <i>Neuromuscular Disorders</i> , 2008, 18, 656-666.	0.6	81
185	Periorbital Ecchymoses Are Not Pathognomonic of the Light-chain Type of Amyloidosis. <i>Acta Dermato-Venereologica</i> , 2007, 87, 544-545.	1.3	7
186	M.P.2.13 The French Pompe registry: A prospective clinical survey of patients with late onset Pompe disease in France. <i>Neuromuscular Disorders</i> , 2007, 17, 796-797.	0.6	0
187	M.P.4.02 Permanent muscle weakness in McArdle disease. <i>Neuromuscular Disorders</i> , 2007, 17, 859-860.	0.6	1
188	Combination of IFN-1a (Avonex [®] 1/2) and mycophenolate mofetil (Cellcept [®] 1/2) in multiple sclerosis. <i>European Journal of Neurology</i> , 2007, 14, 85-89.	3.3	42
189	NIPA1 (SPG6) mutations are a rare cause of autosomal dominant spastic paraplegia in Europe. <i>Neurogenetics</i> , 2007, 8, 155-157.	1.4	23
190	Unusual ocular motor findings in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006, 243, 91-95.	0.6	41
191	A new case of autosomal dominant myotonia associated with the V1589M missense mutation in the muscle sodium channel gene and its phenotypic classification. <i>Neuromuscular Disorders</i> , 2006, 16, 321-324.	0.6	20
192	SIMPLE mutation analysis in dominant demyelinating Charcot-Marie-Tooth disease: three novel mutations. <i>Journal of the Peripheral Nervous System</i> , 2006, 11, 148-155.	3.1	59
193	Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. <i>Journal of Rheumatology</i> , 2006, 33, 709-11.	2.0	24
194	Brain MRI in late-onset multiple sclerosis. <i>European Journal of Neurology</i> , 2005, 12, 241-244.	3.3	26
195	One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 360-363.	3.0	31
196	Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin. <i>Archives of Neurology</i> , 2005, 62, 1689.	4.5	169
197	Autoimmune hepatitis and multiple sclerosis: a coincidental association?. <i>Multiple Sclerosis Journal</i> , 2005, 11, 691-693.	3.0	44
198	A family with a novel frameshift mutation in the PMP22 gene (c.433_434insC) causing a phenotype of hereditary neuropathy with liability to pressure palsies. <i>Neuromuscular Disorders</i> , 2005, 15, 493-497.	0.6	9

#	ARTICLE	IF	CITATIONS
199	Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 596-597.	3.0	88
200	CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. <i>European Journal of Neurology</i> , 2004, 11, 525-529.	3.3	83
201	Patients with Familial Partial Lipodystrophy of the Dunnigan Type Due to a LMNAR482W Mutation Show Muscular and Cardiac Abnormalities. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5337-5346.	3.6	106
202	GUG is an efficient initiation codon to translate the human mitochondrial ATP6 gene. <i>Biochemical and Biophysical Research Communications</i> , 2004, 313, 687-693.	2.1	29
203	Vocal cord and diaphragm paralysis, as clinical features of a French family with autosomal recessive Charot-Marie-Tooth disease, associated with a new mutation in the GDAP1 gene. <i>Neuromuscular Disorders</i> , 2004, 14, 261-264.	0.6	38
204	Double-blind crossover study with dolasetron mesilate, a 5-HT ₃ receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 1190-1194.	3.6	22
205	Prospective study of patients presenting with acute partial transverse myelopathy. <i>Journal of Neurology</i> , 2003, 250, 1447-1452.	3.6	67
206	Multiple sclerosis, interferon beta and clinical thyroid dysfunction. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 154-157.	2.1	30
207	Autonomic and respiratory dysfunction in Charcot-Marie-Tooth disease due to Thr124Met mutation in the myelin protein zero gene. <i>Clinical Neurophysiology</i> , 2003, 114, 1609-1614.	1.5	48
208	Multiple sclerosis and depression: influence of interferon b therapy. <i>Multiple Sclerosis Journal</i> , 2003, 9, 284-288.	3.0	67
209	Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 521-525.	3.0	131
210	Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. <i>Journal of the Neurological Sciences</i> , 2002, 197, 57-61.	0.6	182
211	Interferon β 1a (Avonex [®]) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability. <i>Journal of Neurology</i> , 2002, 249, 184-187.	3.6	9
212	Congenital myopathy with central cores and fingerprint bodies in association with malignant hyperthermia susceptibility. <i>Neuromuscular Disorders</i> , 2001, 11, 538-541.	0.6	12
213	Bronchiolitis obliterans with organising pneumonia during interferon β -1a treatment. <i>Lancet</i> , The, 2001, 357, 751.	13.7	17
214	Pupillary disturbances in multiple sclerosis: correlation with MRI findings. <i>Journal of the Neurological Sciences</i> , 2001, 188, 37-41.	0.6	39
215	Guillain-Barré syndrome resembling brainstem death in a patient with brain injury. <i>Journal of Neurology</i> , 2001, 248, 430-432.	3.6	23
216	Autonomic dysfunction in multiple sclerosis: cervical spinal cord atrophy correlates. <i>Journal of Neurology</i> , 2001, 248, 297-303.	3.6	57

#	ARTICLE	IF	CITATIONS
217	Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. <i>Brain</i> , 2001, 124, 1509-1521.	7.6	193
218	Multiple sclerosis with normal neuro-ophthalmological work-up: results of focal stimulations induced by a scanning laser ophthalmoscope. <i>Acta Neurologica Scandinavica</i> , 2000, 101, 311-314.	2.1	1
219	Paroxysmal kinesigenic choreoathetosis as a presenting symptom of multiple sclerosis. <i>Journal of Neurology</i> , 2000, 247, 478-480.	3.6	24
220	Visual evoked potentials study in chronic idiopathic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2000, 111, 2285-2291.	1.5	39
221	Unusual MR findings of the brain stem in arterial hypertension. <i>American Journal of Neuroradiology</i> , 2000, 21, 391-4.	2.4	73
222	Specific pattern of nitric oxide synthase expression in glial cells after hippocampal injury. , 1998, 22, 329-337.		30
223	Follow-Up of Patients with History of Cervical Artery Dissection. <i>Cerebrovascular Diseases</i> , 1995, 5, 43-49.	1.7	148
224	Fourth meeting of the European Neurological Society 25-29 June 1994 Barcelona, Spain. <i>Journal of Neurology</i> , 1994, 241, 1-164.	3.6	20